We will be collaborating with centers which are generating genetic expression data on both human tumors and normal tissues to seek candidate proteins suitable for immune attack. These will be attacked by vaccinating mice bearing human molecules important to immune recognition of cancer (MHC;major histocompatibility complex molecules). Resulting responding T-cells will be cloned. If they are then confirmed to react with appropriate human tumors, the mouse T-cell receptors can be directly introduced into human T-cells where they have already been shown to function in vitro as well as in vivo (in clincal protocols against melanoma in the Surgery Branch). In addition, we will be studying the inhibitory mechanisms which appear to impede the accumulation and function of tumor-reactive T-cells in non-melanoma tumors, a phenomenon absent in most melanomas (which can be shown to harbor such cells in the majority of cases). For this effort we will be studying human renal cancer because clinical evidence indicates that an immune response is likely to be present as it can respond to a variety of immunotherapies. Yet efforts to clone tumor-reactive T-cells from renal cancer patients have not been very successful. Known immune inhibitory circuits will be examined to determine if they are active in kidney cancer and if they can be shut off, allowing the recovery of tumor-reactive immune cells. Again the clinical translational thrust of this work will be to clone the T-cell receptors and engineer them into the normal lymphocytes of other patients with renal cancer for clinical administration. We have already identified a thyroid cancer antigen and cloned T-cells from vaccinated mice. We will be further investigating candidate proteins on human liver cancer and constructing receptors to determine if they recognize human liver cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Yang, James C (2017) Debugging the Black Box. Cancer Discov 7:250-251
Jin, Linchun; Ge, Haitao; Long, Yu et al. (2017) CD70, a novel target of CAR-T-cell therapy for gliomas. Neuro Oncol :
Klemen, Nicholas D; Feingold, Paul L; Goff, Stephanie L et al. (2017) Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Ann Surg Oncol 24:135-141
Wang, Qiong J; Yu, Zhiya; Hanada, Ken-Ichi et al. (2017) Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clin Cancer Res 23:2267-2276
Yang, James C (2016) The Immunotherapy Roadmap. Clin Cancer Res 22:275-6
Yang, James C; Rosenberg, Steven A (2016) Adoptive T-Cell Therapy for Cancer. Adv Immunol 130:279-94
Gros, Alena; Parkhurst, Maria R; Tran, Eric et al. (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22:433-8
Gros, Alena; Robbins, Paul F; Yao, Xin et al. (2014) PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124:2246-59
Tran, Eric; Turcotte, Simon; Gros, Alena et al. (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641-5
Lu, Yong-Chen; Yao, Xin; Li, Yong F et al. (2013) Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol 190:6034-42

Showing the most recent 10 out of 11 publications